Cullinan Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.71 | $-0.81 | -14.1% | Miss |
| Q12026 FY2026 | $-0.80 | $-0.75 | +6.3% | Beat |
| Q42025 FY2025 | $-0.80 | $-0.77 | +3.8% | Beat |
Back to CGEM overview · CGEM holders · CGEM KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.